Rocket Pharmaceuticals 過去の業績

過去基準チェック /06

Rocket Pharmaceuticalsの収益は年平均-22.4%で減少しているが、Biotechs業界はgrowingで7.7%年平均の収益となった。

主要情報

-22.4%

収益成長率

-10.8%

EPS成長率

Biotechs 業界の成長	-14.6%
収益成長率	n/a
株主資本利益率	-78.3%
ネット・マージン	n/a
前回の決算情報	30 Sep 2024

Recent updates

収支内訳

Rocket Pharmaceuticals の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

DB:9IP1 収益、費用、利益 ( )USD Millions
日付	収益	G+A経費	研究開発費
30 Sep 24	-258	98	176
30 Jun 24	-253	90	180
31 Mar 24	-249	80	185
31 Dec 23	-246	73	186
30 Sep 23	-253	68	194
30 Jun 23	-249	64	191
31 Mar 23	-237	60	181
31 Dec 22	-222	56	165
30 Sep 22	-199	51	148
30 Jun 22	-192	46	144
31 Mar 22	-172	43	127
31 Dec 21	-169	42	124
30 Sep 21	-186	40	142
30 Jun 21	-165	35	124
31 Mar 21	-155	33	116
31 Dec 20	-140	29	105
30 Sep 20	-99	25	70
30 Jun 20	-89	23	63
31 Mar 20	-82	21	60
31 Dec 19	-77	18	58
30 Sep 19	-85	15	67
30 Jun 19	-82	13	66
31 Mar 19	-79	8	62
31 Dec 18	-75	13	53
30 Sep 18	-54	11	34
30 Jun 18	-44	11	26
31 Mar 18	-32	13	18
31 Dec 17	-20	5	15
30 Sep 17	-16	4	12
30 Jun 17	-11	2	9
31 Mar 17	-9	2	7
31 Dec 16	-8	2	6

質の高い収益: 9IP1は現在利益が出ていません。

利益率の向上: 9IP1は現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: 9IP1は利益が出ておらず、過去 5 年間で損失は年間22.4%の割合で増加しています。

成長の加速: 9IP1の過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: 9IP1は利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( -18.2% ) と比較することは困難です。

株主資本利益率

高いROE: 9IP1は現在利益が出ていないため、自己資本利益率 ( -78.26% ) はマイナスです。

Rocket Pharmaceuticals 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

Recent updates

New minor risk - Profitability

Rocket Pharmaceuticals, Inc. Announces Completion of Enrollment in Phase 2 Pivotal Trial of RP-A501 for the Treatment of Danon Disease

Rocket Pharmaceuticals, Inc. Appoints Mikael Dolsten to the Board

Rocket Pharmaceuticals, Inc. Provides Regulatory Update on KRESLADI™ (marnetegragene autotemcel; marne-cel)

Rocket Pharmaceuticals Presents Positive Data from Lv Hematology Portfolio At the 27Th Annual Meeting of the American Society of Gene and Cell Therapy (Asgct)

New minor risk - Profitability

Rocket Pharmaceuticals, Inc., Annual General Meeting, Jun 13, 2024

Insider recently sold €284k worth of stock

Rocket Pharmaceuticals, Inc. Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia

Rocket Pharmaceuticals, Inc. Announces Executive Appointments

No longer forecast to breakeven

CEO & Director recently sold €561k worth of stock

Rocket Pharmaceuticals, Inc. Announces Update on Fda Review Timeline of Kresladi™ (Marnetegragene Autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (Lad-I)

New minor risk - Profitability

Forecast to breakeven in 2026

Rocket Pharmaceuticals, Inc. Appoints R. Keith Woods as Independent, Non-Executive Director

New major risk - Revenue and earnings growth

New minor risk - Profitability

Rocket Pharmaceuticals, Inc. Announces Fda Acceptance of Biologics License Application with Priority Review for Rp-L201 (Marnetegragene Autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (Lad-I)

Rocket Pharmaceuticals Receives European Medicines Agency (Ema) Priority Medicines (Prime) Designation for RP-A501 Gene Therapy for Danon Disease

CEO & Director recently sold €81k worth of stock

Rocket Pharmaceuticals, Inc. Announces FDA Clearance of IND for Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy (ACM)

Insufficient new directors

Insider recently sold €64k worth of stock

Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A501 Gene Therapy for Danon Disease

Rocket Pharmaceuticals Expands Cardiac Gene Therapy Portfolio with Addition of RP-A601 for PKP2-ACM

Rocket Pharmaceuticals, Inc. Provides Update on Anticipated Registration Path for RP-A501 in Danon Disease Following End-Of-Phase 1 FDA Meeting

Rocket Pharmaceuticals, Inc. (NasdaqGM:RCKT) completed the acquisition of Renovacor, Inc. (NYSEAM:RCOR) from RTW Investments, LP, Chardan Investments 2, LLC and others,

Rocket Pharmaceuticals, Inc. Announces Presentations Highlighting Lentiviral Gene Therapies at the 29th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)

Rocket Pharmaceuticals Announces Positive Updates from Phase 1 Clinical Trial for RP-A501 in Danon Disease at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022

Rocket Pharmaceuticals, Inc. (NasdaqGM:RCKT) entered into a definitive agreement to acquire Renovacor, Inc. (NYSEAM:RCOR) from RTW Investments, LP and others for $46.7 million.

Rocket Pharmaceuticals, Inc. (NasdaqGM:RCKT) entered into a definitive agreement to acquire Renovacor, Inc. (NYSEAM:RCOR) from RTW Investments, LP and others for $46.7 million.

Rocket Pharmaceuticals, Inc. Appoints Mayo Pujols as Chief Technical Officer and Executive Vice President

Rocket Pharmaceuticals Presents Positive Top-Line Data from Severe Leukocyte Adhesion Deficiency-I Program At the 25Th Annual Meeting of the American Society of Gene and Cell Therapy (Asgct)

Rocket Pharmaceuticals, Inc. Presents Positive Clinical Data from Danon Disease, Fanconi Anemia and Pyruvate Kinase Deficiency Programs at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

Rocket Pharmaceuticals, Inc., Annual General Meeting, Jun 13, 2022

Rocket Pharmaceuticals Appoints Fady Malik to Board of Directors

Rocket Pharmaceuticals Appoints Jessie Yeung as Vice President of Investor Relations and Corporate Finance

CEO & Director recently bought €334k worth of stock

Rocket Pharmaceuticals Presents Positive Clinical Data from Company’s Lentiviral Gene Therapies for Treatment of Fanconi Anemia, LAD-I and PKD at the 63rd American Society of Hematology (ASH) Annual Meeting

Rocket Pharmaceuticals, Inc. Presents Positive Clinical Data from Fanconi Anemia, Leukocyte Adhesion Deficiency-I, and Pyruvate Kinase Deficiency Programs at 24Th Annual Meeting of the American Society of Gene and Cell Therapy

Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy Designation for RP-L201 Gene Therapy for Leukocyte Adhesion Deficiency-I

New 90-day high: €52.50

Rocket Pharmaceuticals, Inc. Announces Executive Appointments

Rocket Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $260.000048 million.

Rocket Pharmaceuticals Presents Positive Clinical Data from its Fanconi Anemia and Leukocyte Adhesion Deficiency-I Programs at the 62nd American Society of Hematology Annual Meeting

New 90-day high: €50.00

Rocket Pharmaceuticals Announces Positive Preliminary Clinical Data from Phase 1 Trial of RP-L301 for the Treatment of Pyruvate Kinase Deficiency at the 62nd American Society of Hematology Annual Meeting

New 90-day high: €28.40

Inotek Pharmaceuticals Corporation Receives Funding from the California Institute for Regenerative Medicine for Phase 1 Clinical Trial of RP-L401 for Infantile Malignant Osteopetrosis

Rocket Pharmaceuticals, Inc. Presents Positive LAD-L Clinical Update and Comprehensive IMO Preclinical Review At the European Society for Immunodeficiencies 2020 Meeting

New 90-day high: €25.00

New 90-day high - €22.40

Rocket Pharmaceuticals, Inc.(NasdaqGM:RCKT) dropped from Russell Microcap Index

収支内訳

収益と収入の歴史

フリー・キャッシュフローと収益の比較

過去の収益成長分析

株主資本利益率

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

過去基準チェック /06